Review Article
Human Amnion Epithelial Cell Therapy for Chronic Liver Disease
Table 1
Summary of results from studies using hAEC-based therapies in models of liver disease.
| Study | Injury model | hAEC treatment | Main results |
| Manuelpillai et al. [22] | C57BL/6 mice administered CCl4 twice weekly for 4 weeks | Intraperitoneal injection of whole hAECs | Decreased liver injury, inflammation, and fibrosis | Sant’Anna et al. [105] | Bile duct ligation in Wistar rats for 6 weeks | Amniotic membrane place over ligation site | Reduced liver fibrosis | Manuelpillai et al. [36] | C57BL/6 mice administered CCl4 twice weekly for 12 weeks | Single and double dose of whole hAECs by intraperitoneal injection | Decrease fibrosis, decreased macrophage infiltration, increased M2 polarisation, and reduced T-cell infiltration | Ricci et al. [106] | Bile duct ligation in Sprague Dawley rats for 6 weeks | Fresh or cryopreserved amniotic membrane place over ligation site | Fresh and cryopreserved amniotic membrane produced the same antifibrotic effects | Alhomrani et al. [24] | C57BL/6 mice administered CCl4 twice weekly for 12 weeks | Tail vein injection of hAEC-CM or hAEC-derived exosomes | hAEC-CM and exosomes derived from hAECs reduce liver inflammation and fibrosis | Kuk et al. [45] | C57BL/6J mice on a Western fast food diet for 42 weeks | Multiple intraperitoneal injections of either whole hAECs or hAEC-CM | hAEC-CM reduces inflammation and fibrosis |
|
|
CCl4: carbon tetrachloride; hAEC: human amnion epithelial cell; hAEC-CM: human amnion epithelial cell-conditioned medium.
|